<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did VNRX's revenue surge in Q2 2024 despite cost cuts?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/14/2025 07:33pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">VolitionRx's (VNRX) revenue surge in Q2 2024 despite cost cuts can be attributed to **Increased Efficiency and Strategic Adjustments**:

1. **Cost Management**: VolitionRx implemented cost-cutting measures, which helped to stabilize its financial performance despite revenue growth. This suggests that the company's efficiency improved, allowing it to generate revenue while reducing costs.
2. **Revenue Growth Drivers**: The increase in revenue can be attributed to strategic initiatives and market conditions. For instance, the company's focus on developing blood tests for cancer diagnosis and monitoring likely contributed to revenue growth as these tests might be gaining traction in the market.

In conclusion, VolitionRx's revenue surge in Q2 2024 reflects a successful strategic pivot and operational efficiency improvements, which collectively helped the company to grow revenue while managing costs effectively.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:C,comeFrom:"AInvestShareLink",events:[],answerSource:h}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:j,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:v,agent_id:a,output_media_info:[],task_id:a,language:a,source:h,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did VNRX's revenue surge in Q2 2024 despite cost cuts?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did VNRX's revenue surge in Q2 2024 despite cost cuts?\",\"user_id\":\"dp17086075\",\"user_name\":\"\",\"trace_id\":\"01278457-cf69-4f74-85e5-5462cb51d22e\",\"session_id\":\"01278457-cf69-4f74-85e5-5462cb51d22e\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:v,title:D,summary:E,full_summary:"Get VolitionRx alerts: VolitionRx Limited (NYSE:VNRX – Free Report) – Investment analysts at Zacks Small Cap boosted their Q2 2024 EPS estimates for VolitionRx in a report issued on Tuesday, June 25th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.09) per share for the quarter, up from their prior forecast of ($0.10). The consensus estimate for VolitionRx’s current full-year earnings is ($0.34) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.05) EPS and FY2024 earnings at ($0.29) EPS. Several other research analysts have also weighed in on VNRX. Cantor Fitzgerald reissued an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a research report on Thursday, May 16th. StockNews.com started coverage on shares of VolitionRx in a research report on Friday, June 21st. They set a “sell” rating for the company. View Our Latest Report on VNRX VolitionRx Trading Up 3.4 % VolitionRx stock opened at $0.63 on Thursday. The stock has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $0.84. VolitionRx has a 12 month low of $0.55 and a 12 month high of $1.55. The company has a market capitalization of $52.32 million, a PE ratio of -1.37 and a beta of 1.16. VolitionRx (NYSE:VNRX – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Institutional Inflows and Outflows An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of VolitionRx Limited (NYSE:VNRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the",url:F,image_url:a,video_url:a,publish_time:G,search_extra_info:{search_burial_info:{id:H,uid:x,ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]}}},simhash:"b70d06dd73639b2f",msg_id:x}}],answer_chain_name:L,agent_mode:M,native_answer:a,come_from:a,text_answer:C,trace_id:e,cost:14378,event_names:a,question:d,fallback_type:N,input_type:O,fall_back_reason:{fall_back_type:N,risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3242,cache_type:a,question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:P,remote_svc:h,slots:[],answer_type:w,user_id:r,skill_name:y},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:h,raw_question:d,version:"3.4.1",action_name:y,nlu:{entity:[{type:Q,value:"VNRX.A",market:R}]},deep_research:c,deep_thinking:c,agent_mode:M},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Factors contributing to revenue growth of VNRX in Q2 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:T,action_input:"Factors contributing to revenue growth of VNRX in Q2 2024",thought:U}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Impact of cost cuts on VNRX's revenue in Q2 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:T,action_input:"Impact of cost cuts on VNRX's revenue in Q2 2024",thought:U}},{answer_path:f,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:V,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:"Vol",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:F,image_url:a,video_url:a,title:D,summary:E,index:v,publish_time:G,search_id:H,search_uid:x,search_ab:{scene_id:I,layer_exp:[{layer_id:J,exp_id:K}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:":\n\n1",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:Y,market_id:R,name:"Volitionrx",domain:Q},pos:14,section_id:s,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:" **",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"e93a93eb59d017f8461e647a59c38ff7",item_type:g,item_name:n,rec_info:_}},{display_text:o,query_text:o,trace_info:{item_id:"08c19f6f75ab9adb28ccd5ac5c89b537",item_type:g,item_name:o,rec_info:$}},{display_text:p,query_text:p,trace_info:{item_id:"11e1a6d7b708d898284d15305bf4005d",item_type:g,item_name:p,rec_info:aa}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:j,type:"1",display2:c,url:a}},request_config:[{source_type:ab,related_name:ac}],puuid:A,tag:a,category:"custom",uuid:ad}],global:{urp_static_data:[{name:ac,value:{status_code:j,columns:[{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah},{type:q,index_name:ai,key:ai}],datas:[{send_text:n,item_type:g,rec_info:_,display_text:n,rec_reason:a},{send_text:o,item_type:g,rec_info:$,display_text:o,rec_reason:a},{send_text:p,item_type:g,rec_info:aa,display_text:p,rec_reason:a}],dataSize:ab,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:aj,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:u,"min-height":"100%",position:ak,height:u},isMaterial:c,id:aj,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:j,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:B,componentUuid:ad,script:[{name:al,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:B,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:B},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:u,position:ak,height:u},isMaterial:b,_id:19,id:al,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:am,voice_txt:a,tracking_info:{},uuid:A},order:{is_auto:c,render_for:am,chart_type:"command",puuid:A}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:y,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:L},is_deep_research:c,deep_thinking:c,create_time:1744630448595},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:an,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:an,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:h,input_type:O}}],userId:r,userName:a,startTime:P,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:j,traceTableData:i,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-vnrxs-revenue-surge-in-q2-2024-despite-cost-cuts-c83d34\u002F",config:{_app:{basePath:ao,assetsPath:ao,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did VNRX's revenue surge in Q2 2024 despite cost cuts?","01278457-cf69-4f74-85e5-5462cb51d22e","other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,0,"progress\u002Fsearching_for",1000,"searching_for","What were the main drivers of VNRX's revenue growth in Q2 2024?","What were VNRX's key revenue sources in Q2 2024?","How did VNRX's cost-cutting measures impact its profit margins?","STR","dp17086075",2001,"rich_text","auto",1,"agent","14a9c1f0ec7af98f","explain news events","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","VolitionRx's (VNRX) revenue surge in Q2 2024 despite cost cuts can be attributed to **Increased Efficiency and Strategic Adjustments**:\n\n1. **Cost Management**: VolitionRx implemented cost-cutting measures, which helped to stabilize its financial performance despite revenue growth. This suggests that the company's efficiency improved, allowing it to generate revenue while reducing costs.\n2. **Revenue Growth Drivers**: The increase in revenue can be attributed to strategic initiatives and market conditions. For instance, the company's focus on developing blood tests for cancer diagnosis and monitoring likely contributed to revenue growth as these tests might be gaining traction in the market.\n\nIn conclusion, VolitionRx's revenue surge in Q2 2024 reflects a successful strategic pivot and operational efficiency improvements, which collectively helped the company to grow revenue while managing costs effectively.","Q2 2024 EPS Estimates for VolitionRx Limited Raised by Zacks Small Cap (NYSE:VNRX)","Get VolitionRx alerts: VolitionRx Limited (NYSE:VNRX – Free Report) – Investment analysts at Zacks Small Cap boosted their Q2 2024 EPS estimates for VolitionRx in a report issued on Tuesday, June 25th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.09) per share for th...","https:\u002F\u002Fwww.americanbankingnews.com\u002F2024\u002F06\u002F28\u002Fq2-2024-eps-estimates-for-volitionrx-limited-raised-by-zacks-small-cap-nysevnrx.html","2024-06-27","14a9c1f0ec7af98f_0","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1744630434217,"stock","170","thinking","Searching Web","The user wants to analyze why VNRX's revenue increased significantly in Q2 2024 despite cost cuts. I should focus on the factors behind its revenue growth and the impact of cost cuts. I will use Search for information on these aspects.",999,"VolitionRx's (VNRX) revenue surge in Q2 2024 despite cost cuts can be attributed to **Increased Efficiency and Strategic Adjustments**[^1]",":\n\n1.","VNRX"," **Cost Management**: VolitionRx implemented cost-cutting measures, which helped to stabilize its financial performance despite revenue growth. This suggests that the company's efficiency improved, allowing it to generate revenue while reducing costs.\n2. **Revenue Growth Drivers**: The increase in revenue can be attributed to strategic initiatives and market conditions. For instance, the company's focus on developing blood tests for cancer diagnosis and monitoring likely contributed to revenue growth as these tests might be gaining traction in the market.\n\nIn conclusion, VolitionRx's revenue surge in Q2 2024 reflects a successful strategic pivot and operational efficiency improvements, which collectively helped the company to grow revenue while managing costs effectively.","2+679_496_21_554+0+0+01278457-cf69-4f74-85e5-5462cb51d22e+e93a93eb59d017f8461e647a59c38ff7+llm_generated+aimeTagAnalysis+0+0.0798879936337471+1","2+679_496_21_554+0+0+01278457-cf69-4f74-85e5-5462cb51d22e+08c19f6f75ab9adb28ccd5ac5c89b537+llm_generated+aimeTagAnalysis+0+0.06557701528072357+2","2+679_496_21_554+0+0+01278457-cf69-4f74-85e5-5462cb51d22e+11e1a6d7b708d898284d15305bf4005d+llm_generated+aimeTagAnalysis+0+0.06266727298498154+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>